Trial may herald “more ecstasy, less agony” for GCA patients


Treatment with tocilizumab (Actemra) reduced the need for high-dose steroid treatment and increased the chance of remission for patients with giant cell arteritis, a randomised phase 3 trial shows. Results from the multicentre GiACTA trial were the basis for the Food and Drug Administration’s approval of tocilizumab to treat giant cell arteritis back in May. ...


Already a member? Login to keep reading


OR
© 2017 the limbic